▶주메뉴 바로가기
▶본문 바로가기
South Korea’s bio sector is gaining both attention and traction, with many claiming their successful global expansion. While not all of them can deliver on their word, Daewoong Pharmaceutical is on...
Celltrion ’s founder and Chairman Seo Jung-jin announced on March 26 that the company aims to begin selling its biosimilar Truxima in the US within the second half of this year. Seo -- who is in To...
National Pension Service has decided to oppose key proposals by Samsung Biologics ahead of the company’s scheduled shareholders meeting on March 22. The key proposals include approval of the financi...
SK Biopharmaceuticals, the new drug development unit of South Korea’s telecom-to-energy conglomerate SK Group, announced on March 21 that it has received marketing approval from the US Food and Drug ...
South Korea’s biotherapeutics firm SillaJen announced on March 20 that it has decided to secure additional funds worth 110 billion won ($97.31 million) through issuing convertible bonds. The compa...
Korean pharmaceutical companies have high hopes of leaping forward this year by boosting research and development to develop new drugs. According to a survey conducted by the Korea Pharmaceutical an...
South Korean drug maker Donga Pharmaceutical said on March 18 that it will roll out its diabetes drug Suganon in India next month. India-based pharmaceutical firm Alkem Laboratories won exclusive...
Several South Korean pharmaceutical companies have decided to make new facility investments in a bid to hone their competitiveness, industry sources said on March 18. The decisions, made at annua...
Prosecutors raided South Korea’s main stock exchange on March 15 as part of a probe into alleged accounting fraud by Samsung BioLogics. Investigators from the Seoul Central District Prosecutors’ ...
South Korean internet giant Naver said on March 15 that it has established a joint venture with Daewoong Pharmaceutical to provide medical data analysis services based on its artificial intellige...
Daewoong Pharmaceutical announced on March 14 that it is negotiating with Vietnam’s second-biggest drug maker Traphaco to expand its presence in the country. The South Korean firm acquired a 15 per...
SillaJen has delayed its board meeting, which was expected to confirm its decision for securing new funds worth around 220 billion won ($194.89 million), according to industry sources on March 14. ...
South Korea’s biotherapeutics company SillaJen ’s stock price fluctuated after a local news outlet reported that the future of its drug candidate Pexa-Vec was murky. Pexa-Vec, which is undergoing ...
South Korean new drug developer GemVax & KAEL announced on March 13 that it has recruited 90 patients to conduct phase 2 clinical trials of its treatment for Alzheimer’s disease. “Since the trials...
LG Chem, South Korea’s top chemical firm, said on March 11 it has received a $33.4 million grant from the Bill & Melinda Gates Foundation to develop a new combination vaccine. The grant will be u...
[Herald Interview] NYSE hopes to see more Korean firms listing in US
Watchdog orders banks to compensate investors for damages from Lime misselling
National Pension Service gains W72tr for 2020
Provisioning, relief measures to support S. Korean banks’ performance: Fitch
Once-hot P2P lending industry faces tough road ahead
SK Bioscience seeks up to W1.5tr in blockbuster IPO
S. Korean unicorns take big leap with greater global presence
[News Focus] Power struggle? FSC, BOK bicker over revision of payment settlement law